NCT01299610: A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo |
|
|
| Completed | 2 | 25 | Europe | GW870086 2.0%, GW870086 0.2%, FP 0.05%, Placebo | GlaxoSmithKline | Dermatitis, Atopic | 03/11 | 04/11 | | |
2010-022280-35: A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis. |
|
|
| Completed | 2 | 25 | Europe | GW870086X, Flutivate® Creme, GW870086X, Flutivate® Creme, Cream, Flutivate Creme | GlaxoSmithKline | subjects with moderate or severe atopic dermatitis. | | | | |
